Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
June 30 2023 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2023
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On June 16, 2023, Dr. Denise Scots-Knight, Mereo BioPharma Group plcs (the Company) Chief Executive
Officer, purchased 200,000 American Depositary Shares (ADSs), each representing five ordinary shares, nominal value £0.003 per share, of the Company in open market transactions at an average price of approximately $1.42 per ADS. On
June 22, 2023, Christine Fox, the Companys Chief Financial Officer, purchased 10,000 ADSs in open market transactions at an average price of approximately $1.34 per ADS.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: June 30, 2023
|
|
|
MEREO BIOPHARMA GROUP PLC |
|
|
By: |
|
/s/ Charles Sermon |
|
|
Name: Charles Sermon |
|
|
Title: General Counsel |
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From May 2023 to May 2024